Barclays lowered the firm’s price target on Janux Therapeutics (JANX) to $29 from $48 and keeps an Overweight rating on the shares. The firm adjusted price targets in the biotechnology space as part of its 2026 outlook.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Midday Fly By; Kalshi hits $11B valuation, MongoDB reports Q3 beat
- Janux Therapeutics falls -48.4%
- Janux Therapeutics falls -49.4%
- Optimistic Buy Rating for Janux Therapeutics Despite Challenges and Promising Market Potential
- Janux Therapeutics price target lowered to $150 from $200 at Cantor Fitzgerald